Human 4-1BB receptor splicing variant

Abstract

The invention relates to h4-1BBSV receptor polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

What is claimed is:  
     
         1 . An isolated polynucleotide comprising a polynucleotide having at least a 90% identity to a member selected from the group consisting of: 
 (a) a polynucleotide encoding a polypeptide comprising amino acid 1 to amino acid 132 set forth in SEQ ID NO:2;    (b) a polynucleotide encoding a polypeptide comprising amino acid 1 to amino acid 201 set forth in SEQ ID NO:2;    (c) a polynucleotide which is complementary to the polynucleotide of (a) or (b).    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . The polynucleotide of  claim 1  wherein the polynucleotide is RNA.  
     
     
         4 . The polynucleotide of  claim 1  wherein the polynucleotide is genomic DNA.  
     
     
         5 . The polynucleotide of  claim 2  which encodes a polypeptide comprising amino acid 1 to 132 of SEQ ID NO:2.  
     
     
         6 . The polynucleotide of  claim 2  which encodes a polypeptide comprising amino acid 1 to 201 of SEQ ID NO:2.  
     
     
         7 . An isolated polynucleotide comprising a polynucleotide having at least a 90% identity to a member selected from the group consisting of: 
 (a) a polynucleotide which encodes a mature polypeptide having the amino acid sequence expressed by the human cDNA contained in the deposited clone; and    (b) a polynucleotide which is complementary to the polynucleotide of (a).    
     
     
         8 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 1 to nucleotide 947.  
     
     
         9 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 178 to nucleotide 573.  
     
     
         10 . The polynucleotide of  claim 1  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 178 to nucleotide 780.  
     
     
         11 . A vector comprising the DNA of  claim 1 .  
     
     
         12 . A host cell comprising the vector of  claim 11 .  
     
     
         13 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 12  the polypeptide encoded by said DNA.  
     
     
         14 . A process for producing a cell comprising: genetically engineering the cell with the vector of  claim 11  to thereby express the polypeptide encoded by the DNA contained in the vector.  
     
     
         15 . A polypeptide comprising a member selected from the group consisting of: 
 (a) a polypeptide having an amino acid sequence set forth in SEQ ID NO:2;    (b) a polypeptide comprising amino acid 1 to amino acid 132 as set forth in SEQ ID NO:2;    (c) a polypeptide comprising amino acid 1 to amino acid 201 as set forth in SEQ ID NO:2; and    (d) a polypeptide which is at least 85% identical to the polypeptide of (a).    
     
     
         16 . The polypeptide of  claim 15  wherein the polypeptide comprises amino acid 1 to amino acid 132 of SEQ ID NO:2.  
     
     
         17 . A compound which inhibits activation of the polypeptide of  claim 15 .  
     
     
         18 . A compound which activates the polypeptide of  claim 15 .  
     
     
         19 . A method for the treatment of a patient having need of h4-1BBSV receptor comprising: administering to the patient a therapeutically effective amount of the polypeptide of  claim 15  by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.  
     
     
         20 . A method for the treatment of a patient having need to inhibit h4-1BBSV receptor comprising: administering to the patient a therapeutically effective amount of the compound of  claim 17 .  
     
     
         21 . A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of  claim 15 , comprising determining a mutation in a nucleic acid sequence encoding said polypeptide.  
     
     
         22 . A diagnostic process, comprising analyzing for the presence of the polypeptide of  claim 15  in a sample derived from a host.  
     
     
         23 . A method for identifying agonists and antagonists to the polypeptide of  claim 15  comprising: combining the polypeptide, a ligand known to bind to the polypeptide, and a compound to be screened under conditions where the ligand binds to the polypeptide and determining whether the compound inhibits or enhances a signal generated by the polypeptide.  
     
     
         24 . The polypeptide of  claim 15  wherein the polypeptide is a soluble fragment of the polypeptide and is capable of binding a ligand for the receptor.  
     
     
         25 . A diagnostic process, comprising analyzing for the presence of the polypeptide of  claim 24  in a sample derived from a host.